S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Arnon P. Kater(Amsterdam University Medical Centers), Barbara Dreta(University Hospital Centre Zagreb), Gimena dos Santos(Northwestern University), Christos Demosthenous(Mayo Clinic), Kamel Laribi(Centre Hospitalier du Mans), Mehreen Ali Khan(National Institute Of Blood Disease and Bone Marrow Transplantation), Rosa Collado(Hospital General Universitario De Valencia), Ajay Gogia(All India Institute of Medical Sciences Raipur), Romain Guièze(Broad Institute), Rocío García‐Serra(Hospital General Universitario De Valencia), Alessandro Gozzetti(University of Siena), Lydia Scarfò(IRCCS Ospedale San Raffaele), Shaimaa El‐Ashwah(Mansoura University), Ramona Cassin(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Ritu Gupta(Chandigarh University), Alberto Fresa(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mar Bellido(University Medical Center Groningen), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Isabel González-Gascón-y-Marín(University Hospital Centre Zagreb), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Miguel Alcoceba(Instituto de Investigación Biomédica de Salamanca), Alicia Enrico(Hospital Italiano La Plata), Eleftheria Hatzimichael(Thomas Jefferson University), Zadie Davis(Royal Bournemouth Hospital), Sean Harrop(The University of Melbourne), Dimitra Chamou(Centre for Research and Technology Hellas), Volkan Karakuş(Antalya Eğitim ve Araştırma Hastanesi), Jana Kotašková(Central European Institute of Technology), Eva Gimeno(Hospital Del Mar), Valerio Guarente(University of Perugia), Fontanet Bijou(Institut Bergonié), Sofia Chatzileontiadou(AHEPA University Hospital), Maria Dimou(National and Kapodistrian University of Athens), Eva Minga(Centre for Research and Technology Hellas), Ozren Jakšić(University of Zagreb), Luca Inchiappa(Institut Paoli-Calmettes), Francesca Bacchiarri(University of Siena), Maria Efstathopoulou(Mansoura University), Elżbieta Kalicińska(The University of Melbourne), Andrea Galitzia(Ospedale di Prato Santo Stefano), Salem Al‐Shemari(Kuwait University), Ángeles Medina(Hospital Costa del Sol), Yair Herishanu(Tel Aviv University), David Donaldson(Endometriosis UK), Susanne R. Janssen(Tel Aviv University), Thérèse Aurran‐Schleinitz(Institut Paoli-Calmettes), Sara Galimberti(University of Pisa), Anne Calleja(Institut Paoli-Calmettes), Georgios Karakatsoulis(University of Ioannina)
Cited by 0
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
|The Lancet|2007|679
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568